Idenix Pharmaceuticals LLC
(NASDAQ : IDIX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. -0.96%92.131.9%$1145.22m
JNJJohnson & Johnson -0.87%144.440.7%$1085.68m
BMYBristol-Myers Squibb Co. -0.57%60.791.0%$940.95m
PFEPfizer Inc. 0.64%37.500.9%$816.71m
MRKMerck & Co., Inc. -0.22%76.380.7%$776.51m
LLYEli Lilly & Co. -0.69%151.231.1%$447.35m
AZNAstraZeneca Plc -0.11%55.221.2%$249.77m
NVSNovartis AG -0.09%84.910.2%$158.95m
GSKGlaxoSmithKline Plc -0.37%40.880.2%$141.36m
BHCBausch Health Cos., Inc. -2.26%17.770.0%$113.04m
SNYSanofi -0.30%47.300.2%$86.66m
NVONovo Nordisk A/S 0.05%64.850.1%$84.91m
RGENRepligen Corp. -0.57%139.517.1%$72.80m
ARCTArcturus Therapeutics Holdings, Inc. 7.71%58.270.0%$57.13m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 11.80%58.370.0%$43.19m

Company Profile

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the Company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. The Company has also developed products and drug candidates for the treatment of hepatitis B virus (HBV), human immunodeficiency virus type I (HIV) and acquired immune deficiency syndrome (AIDS).